Illumina Inc. diskutieren

Illumina, Inc. (NASDAQ: ILMN) was upgraded by analysts at Daiwa Capital Markets from a "neutral" rating to a "buy" rating. They now have a $154.00 price target on the stock, up previously from $120.00.

Illumina, Inc. (NASDAQ: ILMN) was upgraded by analysts at Daiwa America to a "strong-buy" rating.

Illumina, Inc. (NASDAQ: ILMN) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.

Illumina, Inc. (NASDAQ: ILMN) was upgraded by analysts at Argus from a "hold" rating to a "buy" rating.

Hey there, fellow investors! I've been diving into Illumina lately, and I've got to say, I'm pretty excited about what I'm seeing. Sure, they've had a rough couple of years, but it looks like they might be turning the corner. First off, that EU court ruling is a big win for Illumina. Not only does it save them a hefty €432 million fine, but it also shows they're not afraid to stand up for themselves. That's the kind of grit I like to see in a company! Now, let's talk about their tech. Illumina's not just riding the AI wave - they're making waves of their own. Their PrimateAI-3D tool is like a crystal ball for genetic diseases. It's the kind of innovation that could revolutionize healthcare. And speaking of revolutions, have you seen their earnings forecast? It's like watching a rocket take off. Their EPS estimates have more than doubled in just two months! That's the kind of momentum that gets my investor senses tingling. Sure, their P/E ratio is a bit high at 34.3x, but in the world of biotech, that's not too shabby. Plus, with their earnings expected to grow by 24% next year, they might just grow into that valuation. Now, I'm not saying Illumina is a guaranteed moonshot. They've still got challenges ahead, and the market can be as unpredictable as a cat in a room full of laser pointers. But with their innovative tech, improving financials, and recent legal victories, I think Illumina might just have what it takes to light up your portfolio. What do you think? Ready to illuminate your investment strategy with ILMN?

Illumina, Inc. (NASDAQ: ILMN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $252.00 price target on the stock.

Illumina, Inc. (NASDAQ: ILMN) had its price target raised by analysts at Leerink Partners from $160.00 to $200.00. They now have an "outperform" rating on the stock.

Illumina, Inc. (NASDAQ: ILMN) was upgraded by analysts at Hsbc Global Res from a "hold" rating to a "strong-buy" rating.

Illumina, Inc. (NASDAQ: ILMN) had its price target raised by analysts at Citigroup Inc. from $155.00 to $190.00. They now have a "buy" rating on the stock.

Illumina, Inc. (NASDAQ: ILMN) had its price target raised by analysts at Royal Bank of Canada from $252.00 to $254.00. They now have an "outperform" rating on the stock.

Illumina, Inc. (NASDAQ: ILMN) had its price target raised by analysts at TD Cowen from $166.00 to $177.00. They now have a "buy" rating on the stock.

Illumina, Inc. (NASDAQ: ILMN) had its price target lowered by analysts at Piper Sandler from $195.00 to $185.00. They now have an "overweight" rating on the stock.

Illumina, Inc. (NASDAQ: ILMN) had its price target raised by analysts at Stephens from $170.00 to $184.00. They now have an "overweight" rating on the stock.

Illumina, Inc. (NASDAQ: ILMN) had its price target lowered by analysts at Guggenheim from $170.00 to $150.00. They now have a "buy" rating on the stock.

Illumina, Inc. (NASDAQ: ILMN) had its price target lowered by analysts at Royal Bank of Canada from $250.00 to $247.00. They now have an "outperform" rating on the stock.

Illumina, Inc. (NASDAQ: ILMN) was downgraded by analysts at Barclays PLC from an "equal weight" rating to an "underweight" rating. They now have a $100.00 price target on the stock, down previously from $130.00.

Illumina, Inc. (NASDAQ: ILMN) had its price target raised by analysts at Piper Sandler from $185.00 to $190.00. They now have an "overweight" rating on the stock.

Illumina, Inc. (NASDAQ: ILMN) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $156.00 price target on the stock.

Illumina, Inc. (NASDAQ: ILMN) had its "underweight" rating re-affirmed by analysts at Barclays PLC.